Overview

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

Status:
Not yet recruiting

Trial end date:
2030-02-01

Target enrollment:

Participant gender:

Summary

The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better results than the current (standard of care) treatments. This study will examine the tolerability and efficacy of this combination therapy for all participants and the ability of this combination therapy to shrink or prevent MM from returning.

Phase:

Phase 2

Details

Lead Sponsor:

Carl Ola Landgren, MD, PhD

Collaborator:

Bristol-Myers Squibb

Treatments:

Acetaminophen
Daratumumab
Dexamethasone
Diphenhydramine
Montelukast
Promethazine